Johannes Jacob Pieter Kastelein, Chief Scientific Officer at NewAmsterdam Pharma Co N.V. (NAMS), sold 6,000 shares at $33.25 ($200K) on 2026-01-05, disclosed to the SEC on 2026-01-07.
Open-market sale of $200k NAMS by Chief Scientific Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| Filing → |
| NAMS | SELL | 2026-02-24 | $1.6M | — | Filing → |
| NAMS | SELL | 2025-08-25 | $3.7M | — | Filing → |
| NAMS | SELL | 2024-03-27 | $4.1M | — | Filing → |